Literature DB >> 16021509

Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.

Yu-Zhen Feng1, Tanri Shiozawa, Akiko Horiuchi, Hsien-Chang Shih, Tsutomu Miyamoto, Hiroyasu Kashima, Akihisa Suzuki, Toshio Nikaido, Ikuo Konishi.   

Abstract

To further elucidate the significance of p53 mutation in endometrial carcinoma, we investigated it in endometrioid-type endometrial carcinomas showing intratumoral heterogeneous p53 expression. In addition, we also examined the correlation of p53 mutation and cyclin A expression, because we previously reported a topological correlation between the expression of p53 and cyclin A. The p53 mutation in exons 5-8 in 54 cases of endometrial carcinoma showing immunohistochemical expression of p53 was examined using microdissected tissue DNAs. Of the 54 p53-positive endometrial carcinomas, 23 (43%) had p53 mutation with a tendency in histologically higher grade tumors. Ten of the 54 showed a heterogeneous p53 expression, and in 9 of the 10 cases, p53 mutation was present only in p53-positive sites, which were often found in histologically less differentiated areas with elevated Ki-67 in the same tumor. Cyclin A expression was topologically observed in p53-positive areas; however, it was noted in both tumors with (12/23, 52%) and without (18/31, 58%) p53 mutation. These results suggest that p53 mutation is a late event and plays an important role in the acquisition of malignant potentials in endometrioid-type endometrial adenocarcinomas. Unexpectedly, accumulation of the p53 protein itself may be important in cyclin A overexpression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021509     DOI: 10.1007/s00428-005-0029-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

Review 1.  Abnormal cell cycle regulation in malignancy.

Authors:  M Dictor; M Ehinger; F Mertens; J Akervall; J Wennerberg
Journal:  Am J Clin Pathol       Date:  1999-07       Impact factor: 2.493

2.  Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.

Authors:  T Koga; S Hashimoto; K Sugio; I Yoshino; K Nakagawa; Y Yonemitsu; K Sugimachi; K Sueishi
Journal:  Int J Cancer       Date:  2001-07-20       Impact factor: 7.396

3.  Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression.

Authors:  M Yamamoto; M Yoshida; K Ono; T Fujita; N Ohtani-Fujita; T Sakai; T Nikaido
Journal:  Exp Cell Res       Date:  1994-01       Impact factor: 3.905

Review 4.  G1 phase progression: cycling on cue.

Authors:  C J Sherr
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

Review 5.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

6.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.

Authors:  M G Luciani; J R Hutchins; D Zheleva; T R Hupp
Journal:  J Mol Biol       Date:  2000-07-14       Impact factor: 5.469

8.  Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.

Authors:  K Ito; H Sasano; G Matsunaga; S Sato; A Yajima; S Nasim; C T Garret
Journal:  J Pathol       Date:  1997-11       Impact factor: 7.996

Review 9.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 10.  Control of the cell cycle.

Authors:  N E Crompton; N Saydan
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more
  6 in total

1.  Identification of potential serum markers for endometrial cancer using protein expression profiling.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Takayoshi Asakawa; Tomoko Goto; Tsunekazu Kita; Kazuya Kudoh; Junzo Kigawa; Noriaki Sakuragi; Masaru Sakamoto; Toru Sugiyama; Nobuo Yaegashi; Hiroshi Tsuda; Hiroshi Seto; Mieko Shiwa
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

2.  Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target.

Authors:  Ryoichi Asaka; Tsutomu Miyamoto; Yasushi Yamada; Hirofumi Ando; David Hamisi Mvunta; Hisanori Kobara; Tanri Shiozawa
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

Review 3.  Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Authors:  Tanri Shiozawa; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.850

4.  Hspb1 and Tp53 Mutation and Expression Analysis in Cat Mammary Tumors.

Authors:  Rashid Saif; Ali Raza Awan; Leslie Lyons; Barbara Gandolfi; Muhammad Tayyab; Masroor Ellahi Babar; Asim Khalid Mehmood; Zia Ullah; Muhammad Wasim
Journal:  Iran J Biotechnol       Date:  2016-09       Impact factor: 1.671

5.  Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

Authors:  Manouk van Esterik; Inge C Van Gool; Cor D de Kroon; Remi A Nout; Carien L Creutzberg; Vincent T H B M Smit; Tjalling Bosse; Ellen Stelloo
Journal:  Oncotarget       Date:  2017-04-11

6.  SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line.

Authors:  Yongli Zhang; FeiZhou Jiang; Wei Bao; Huilin Zhang; XiaoYing He; Huihui Wang; Xiaoping Wan
Journal:  Cancer Cell Int       Date:  2016-04-08       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.